Effects of switching from a reduced imiglucerase to velaglucerase in type 1 Gaucher disease: Clinical and biochemical outcomes

Haematologica

Volumn 97, Issue 12, 2012, Pages 1850-1854

  van Dussen, Laura ^a   Cox, Timothy M ^b   Hendriks, Erik J ^a   Morris, Elizabeth ^b   Akkerman, Erik M ^a   Maas, Mario ^a   Groener, Johanna E M ^a   Aerts, Johannes M F G ^a   Deegan, Patrick B ^b   Hollak, Carla E M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Platelet count; Type 1 Gaucher disease; Velaglucerase alfa

Indexed keywords

CHITOTRIOSIDASE; HEMOGLOBIN; IMIGLUCERASE; MIGLUSTAT; VELAGLUCERASE ALFA;

ADULT; AGED; ARTICLE; BACKACHE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; GAUCHER DISEASE; HUMAN; LIVER WEIGHT; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; RETROSPECTIVE STUDY; RIB FRACTURE; SPLEEN; SPLENECTOMY; THROMBOCYTE COUNT;

ADULT; AGED; ENZYME REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HEMOGLOBINS; HEXOSAMINIDASES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SPLENECTOMY;

EID: 84870406785     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.059071     Document Type: Article

References (18)

1. Beutler E, Grabowski GA. Gaucher Disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001. p. 3636.
2. Biegstraaten M, van Schaik I, Aerts JM, Hollak CE. 'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. J Inherit Metab Dis. 2008;31(3):337-49.
3. Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA. 1990;87(5):1913-6.
4. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med. 1991;324(21):1464-70.
5. Hollak CE, vom Dahl S., Aerts JM, Belmatoug N, Bembi B, Cohen Y, et al. Force Majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis. 2010;44(1):41-7.
6. US Food and Drug Administration (FDA). FDA labelling information-Vpriv (velaglucerase alfa). 2010.
7. European Medicines Agency (EMA). European Public Assessment Report-Vpriv. 2010.
8. Elstein D, Cohn GM, Wang N, Djordjevic M, Brutaru C, Zimran A. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease. Blood Cells Mol Dis. 2011;46(1): 119-23.
9. Zimran A, Altarescu G, Philips M, Attias D, Jmoudiak M, Deeb M, et al. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood. 2010;115(23):4651-6.
10. Elstein D, Altarescu G, Maayan H, Phillips M, Abrahamov A, Hadas-Halpern I, et al. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: Early Access Program results from Jerusalem. Blood Cells Mol Dis. 2012;48(1):45-50.
11. Czartoryska B, Tylki-Szymanska A, Lugowska A. Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease. Clin Biochem. 2000;33(2): 147-9.
12. Giraldo P, Irun P, Alfonso P, Dalmau J, Fernandez-Galan MA, Figueredo A, et al. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage. Blood Cells Mol Dis. 2011;46(1):115-8.
13. Goldblatt J, Fletcher JM, McGill J, Szer J, Wilson M. Enzyme replacement therapy drug holiday: results from an unexpected shortage of an orphan drug supply in Australia. Blood Cells Mol Dis. 2011;46(1): 107-10.
14. Zimran A, Altarescu G, Elstein D. Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply. Blood Cells Mol Dis. 2011;46(1):111-4.
15. vom Dahl S, Poll LW, Haussinger D. Clinical monitoring after cessation of enzyme replacement therapy in M. Gaucher. Br J Haematol. 2001;113(4):1084-7.
16. Giraldo P, Alfonso P, Atutxa K, Fernandez-Galan MA, Barez A, Franco R, et al. Realworld clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project. Haematologica 2009;94(12):1771-5.
17. Weinreb NJ, Cappellini MD, Cox TM, Giannini EH, Grabowski GA, Hwu WL, et al. A validated disease severity scoring system for adults with type 1 Gaucher disease. Genet Med. 2010;12(1):44-51.
18. Zimran A, Kay A, Gelbart T, Garver P, Thurston D, Saven A, et al. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 1992;71(6):337-53.